Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National screening for transient leukemia in newborns with Down syndrome
NL-OMON19924Recruiting
- Sponsor
- KiKa
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cytarabine in transient leukemia (TAM) and acute myeloid leukemia (AML), sponsored by KiKa. Primary endpoints: Population-based frequency of transient myeloproliferative disorder, Relationship between TMD and ML-DS and 1 more. Started Jan 2008; status: recruiting.
02
Drugs
cytarabine
03
Conditions
transient leukemia (TAM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON19924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19924.